Wednesday, August 30, 2017
Alimera Sciences, Inc., a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that Alimera Sciences Limited, its European subsidiary based in the United Kingdom, has signed a distribution agreement with Horus Pharma S.A.S. (Horus). Under the agreement, Horus will serve as Alimera’s exclusive distributor in France for ILUVIEN®, Alimera's sustained release intravitreal injection for the treatment of diabetic macular edema.
Horus will negotiate with the Comité Economique des Produits de Santé, the Union Nationale des Caisses d’Assurance Maladie, the French National Authority for Health and other French regulatory authorities regarding the appropriate public price and confidential net price for reimbursement for ILUVIEN. In addition, Horus will handle promotion, marketing and commercial activities in France for ILUVIEN.
“ILUVIEN’s unique continuous microdosing enables patients to receive treatment consistently every day for up to three years, which we believe can make a major difference to patients with DME in France,” said Dan Myers, Chief Executive Officer of Alimera. “With the knowledge and experience that the Horus team brings in pricing and reimbursement in France, we are optimistic that this partnership will allow French patients suffering from DME access to ILUVIEN.”
“We are extremely pleased and proud to be the exclusive partner of Alimera Sciences for the distribution of ILUVIEN in France, which represents a great treatment opportunity for patients with DME,” said Claude Claret, Managing Director of Horus Pharma. “At Horus Pharma, we have been developing and looking for innovative products in the field of ophthalmology, in order to provide sustainable and affordable solutions for patients. Today’s announcement is the beginning of a process of providing widespread patient access to a unique treatment, in France.”
